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Transcription factor PAX6 as a novel 
prognostic factor and putative 
tumour suppressor in non-small cell 
lung cancer
Yury Kiselev  1,2,5, Sigve Andersen3,4, Charles Johannessen5, Bjørn Fjukstad6, Karina Standahl 
Olsen7, Helge Stenvold4, Samer Al-Saad  5,8, Tom Donnem3,4, Elin Richardsen5,8, Roy M. 
Bremnes3,4 & Lill-Tove Rasmussen Busund5,8
Lung cancer is the leading cause of cancer deaths. Novel predictive biomarkers are needed to improve 
treatment selection and more accurate prognostication. PAX6 is a transcription factor with a proposed 
tumour suppressor function. Immunohistochemical staining was performed on tissue microarrays from 
335 non-small cell lung cancer (NSCLC) patients for PAX6. Multivariate analyses of clinico-pathological 
variables and disease-specific survival (DSS) was carried out, and phenotypic changes of two NSCLC 
cell lines with knockdown of PAX6 were characterized. While PAX6 expression was only associated 
with a trend of better disease-specific survival (DSS) (p = 0.10), the pN+ subgroup (N = 103) showed 
significant correlation between high PAX6 expression and longer DSS (p = 0.022). Median survival 
for pN + patients with high PAX6 expression was 127.4 months, versus 22.9 months for patients with 
low PAX6 expression. In NCI-H661 cells, knockdown of PAX6 strongly activated serum-stimulated 
migration. In NCI-H460 cells, PAX6 knockdown activated anchorage-independent growth. We did 
not observe any significant effect of PAX6 on proliferation in either of cell lines. Our findings strongly 
support the proposition of PAX6 as a valid and positive prognostic marker in NSCLC in node-positive 
patients. There is a need for further studies, which should provide mechanistical explanation for the role 
of PAX6 in NSCLC.
Despite extensive efforts of research and arrival of novel therapies, lung cancer remains leading cause of cancer 
death globally1 and in the United States2. It is the second leading cause of death from any cause after heart disease 
in the United States3. The 5-year relative survival rate for lung cancer is only about 17%4, in particular due to 
a high proportion of patients with regional or advanced disease at the time of diagnosis5. Treatment of meta-
static non-small cell lung cancer (NSCLC) has limited effect because of either intrinsic or acquired resistance to 
chemotherapy6.
In 2002 it was stated that a plateau was reached for treatment efficacy in NSCLC, which could not be improved 
further with conventional chemotherapeutic drugs7. Yet, some progress has been achieved since then8, mainly 
by the introduction of new targeted drugs and patient selection based on histological subtypes and driver muta-
tions, which define the course of disease and predict drug efficacy9,10. Novel predictive biomarkers for NSCLC are 
needed to allow improved treatment selection and more accurate prognosis11.
Transcription factors in general are tightly connected both to normal development and to cancer12. PAX6 is a 
highly evolutionary conserved transcription factor, belonging to the paired box family. It plays an important role 
in the development of the central nervous system, eyes, nose and endocrine pancreas13. In 2003, PAX6 mRNA 
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expression was first described in a wide range of cancer cell lines14. However, only a limited number of studies 
have investigated PAX6 expression in human malignancies, its biological role in cancer and possible effects on 
survival. Several publications link methylation of the PAX6 gene promoter with patients’ prognosis, and discuss 
its relevance as a biomarker in NSCLC15–17, as well as bladder cancer18, gastric cancer19, oesophageal cancer20, and 
breast cancer21. Only two groups have evaluated the prognostic impact of PAX6 in cancers using gene expression 
data obtained from clinical samples. In gliomas, higher levels of PAX6 mRNA were associated with better sur-
vival22,23. Opposite association was found in a small study of neuroendocrine24 and breast tumors25. Molecular 
biology evidence for PAX6 acting as a tumor suppressor exists mainly for glioblastoma26–28, retinoblastoma29 
and prostate cancer30 cells lines. In contrast, a tumour promoting effect was demonstrated in retinoblastoma31, 
colon adenocarcinoma32 and breast cancer33 cell lines. In view of the cancer cell lines data and more abundant 
knowledge of the role of PAX6 in normal development34, PAX6’s exact functions appear to depend on tissue-, 
molecular- and spatio-temporal contexts. So far, prognostic significance of PAX6 protein expression has been 
investigated only in one study of breast cancer25. Herein, we have investigated the PAX6 protein expression and 
evaluated its prognostic impact in a large NSCLC cohort.
Results
Patient characteristics. The patients’ demographic, clinical and histopathological data are presented in 
Table 1. The median follow-up time of survivors was 86 months (range 48–216). The median patient age was 67 
(range 28–85), 76% were male, 95% had performance status 0–1 and 95% were present or previous smokers. The 
NSCLC tumours comprised 191 squamous cell carcinomas (SCC), 14 adenocarcinomas (AC), 9 adenocarcino-
mas in-situ (ACIS) and 31 large-cell carcinomas (LCC).
Validation of the primary antibody. In order to validate specificity and sensitivity of the chosen primary 
antibody, we employed Western blotting and immunohistochemistry (IHC). Two human NSCLC cell lines with 
endogenous expression of PAX6 were transfected with either PAX6 siRNA or scrambled control siRNA, incu-
bated for 48 hours, lysed and analysed by Western blotting (Fig. 1A; see Fig. S1 for uncropped image). A single 
band of appropriate molecular weight (approximately 48 kD) was observed for both cell lines, and significant 
reduction of the band intensity was noted in samples treated with anti-PAX6 siRNA. Equal loading was controlled 
by staining for actin.
To further validate the anti-PAX6 antibody for use on human FFPE tissue sections, we chose a fragment of 
pancreatic tissue with Langerhans islets, which are known to contain PAX6-positive cells35,36 (Fig. 1B), as positive 
control. Indeed, we observed clear strong nuclear staining with much weaker staining in the cytoplasm. No stain-
ing was seen in the exocrine part of the pancreas.
Expression of PAX6 in NSCLC tissues. We observed nuclear staining for PAX6, often accompanied by 
moderate cytoplasmic staining (Fig. 2). It was detectable exclusively in NSCLC tumour cells, and not in the 
surrounding tumour stroma, or adjacent normal lung tissue. Pattern of positive cells varied across the TMA 
cores from patchy to diffuse. However, we did observe a tendency of higher staining intensity in the tumour cells 
located in proximity to stroma or next to the invasion front. A weak cytoplasmic (but not nuclear) staining was 
sometimes seen in macrophages, which we considered an artefact. Neither nuclear nor cytoplasmic staining were 
observed in adjacent normal lung tissue.
Expression correlations. We found no correlations between PAX6 and clinicopathological variables. 
There were a lot of low grade, but significant correlations, when the PAX6 expression was compared with tumour 
cell expression of molecular markers previously published by our group. Only correlations with a r-value > 0,2 
are presented; IGFBP2 (r = 0.258, p < 0.001), BAD (r = −0.20, p < 0.001), HER1 (r = 0.247, p < 0.001), PTEN 
(r = 0.241, p < 0.001), sAKT (the activated isoform at ser474) (r = 0.292, p < 0.001), trombospondin (r = 0.288, 
p < 0.001), MMP7 (r = 0.272, p < 0.001), TIE2 (r = 0.208, p < 0.001), DLL4 (r = 0.233, p < 0.001) and PDGFA 
(r = −0.278, p < 0.001).
Survival analysis. High PAX6 expression was associated with a trend for better DSS (p = 0.10). When strati-
fying for relevant clinical subgroups, the pN+ subgroup (N = 103) showed a significant association between high 
PAX6 expression and a longer DSS (p = 0.022, Fig. 3). Median survival for pN+ patients with high PAX6 expres-
sion was 127.4 months whereas the same value for patients with low PAX6 expression was only 22.9 months. 
Five-year survivals for the same groups were 59% and 26%, respectively.
In the pN+ subgroup, no other clinical or pathological variables had any prognostic significant impact in 
univariate analysis. Therefore, the multivariate model only included PAX6 expression which gave an unadjusted 
hazard ratio of 1.99 for the low expression versus high expression subgroup (p = 0.024).
To assess PAX6 impact on prognosis in the pN+ category in a model with renowned clinicopathological 
factors, we also introduced WHO PS and pTstage in the model. But these were knocked out in the backward 
conditional model. In the “enter” model which does not remove factors, the impact of PAX6 was even stronger 
(P = 0.022 and HR = 2.08) than unadjusted.
Effect of PAX6 on NSCLC cell migration, proliferation and anchorage-independent growth. In 
order to uncover possible biological effects of PAX6 in NSCLC cells, we evaluated effects of transient knock-
down of PAX6 on cell migration, proliferation and anchorage-independent growth. To study proliferation and 
migration in real time, we employed the xCELLigence platform (Roche). This is a microelectric assay based 
on changing impedance of bottom electrodes in presence of the cells. In NCI-H661 cells, knockdown of PAX6 
strongly activated migration capability, measured as the serum-stimulated migration on xCELLigence plat-
form (Fig. 4A) and supported by the wound healing assay in the Incucyte instrument (Supplementary Fig. 3). 
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≤65 years 156 (47) 98 56
>65 years 179 (53) NR 60
Sex 0.22
  Female 82 (24) 190 64
  Male 253 (76) 98 56
Smoking status 0.26
  Never 15 (5) 19 43
  Previous 105 (31) 84 55
  Present 215 (64) NR 60
Performance status 0.016
  0 197 (59) NR 63
  1 120 (36) 64 52
  2 18 (5) 25 33
Weight loss 0.76
  <10% 303 (90) 190 58
  >10% 32 (10) 98 57
Histology 0.028
  Squamous cell carcinoma 191 (57) NR 66
  Adenocarcinoma 113 (34) 54 46
  Large cell carcinoma 31 (9) 98 56
Differentiation  <0.001
  Poor 138 (41) 47 47
  Moderate 144 (43) 190 65
  Well 53 (16) NR 68
Surgical procedure 0.007
  Wedge + Lobectomy 243 (73) 190 62
  Pneumectomy 92 (27) 37 47
pStage  <0.001
  pI 157 (47) NR 72
  pII 136 (41) 62 51
  pIIIA 42 (12) 17 24
pT-status  <0.001
  1 85 (25) 190 75
  2 188 (56) 84 57
  3 62 (19) 25 37
pN-status  <0.001
  0 232 (69) NR 67
  1 76 (23) 35 43
  2 27 (8) 18 18
Surgical margins 0.37
  Free 307 (92) 190 59
  Not free 28 (8) 47 48
Vascular infiltration  <0.001
  No 284 (85) 190 62
  Yes 51 (15) 27 33
Pax6 expression 335 (100) 0.10
  High 94 (28) NR 67
  Low 241 (72) 75 55
Pax6 expression in AC 113 (34) 0.32
  High 22 (7) NR 57
  Low 91 (27) 47 44
Pax6 expression in SCC 191 (57) 0.52
  High 60 (18) NR 73
  Low 131 (39) NR 63
Continued
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NCI-H460 cells did not exhibit ability to migrate across the membrane after transfection with either PAX6 siRNA 
or control siRNA. We did not observe any significant effect of PAX6 on proliferation rate of either cell lines 
(NCI-H460 and NCI-H661) when measured by xCELLigence platform (Fig. 4B,C). NCI-H460 cells subjected to 
Characteristics






Pax6 expression in pN+ 103 (31) 0.022
  High 33 (10) 127 59
  Low 70 (21) 23 26
Table 1. Prognostic clinicopathologic variables as predictors of disease-specific survival in 335 NSCLC-
patients. AC – adenocarcinoma, NR – not reached, SCC – squamous cell carcinoma.
Figure 1. Validation of PAX6 antibody. (A) Two NSCLC cell lines were transfected with siRNA against human 
PAX6 or control scrambled siRNA. Cell lysates were tested for PAX6 using Western blotting. (B) FFPE sections 
of pancreas with Langerhans islands stained for PAX6.
Figure 2. Immunohistochemical staining for PAX6 in NSCLC. NSCLC tissue with negative (A), weak (B), 
average (C) and strong (D) staining for PAX6.
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PAX6 knockdown exhibited profoundly more active anchorage-independent growth in soft agar, compared to 
controls (Fig. 4D). Neither treated nor control NCI-H661 cells were capable of making colonies in soft agar assay. 
Efficiency of knockdown was controlled using RT-PCR: fold change for PAX6 in NCI-H460 cells was −5,3 ± 0,3, 
and in NCI-H661 −7,1 ± 0,9 (Fig. 5).
Effect of PAX6 on expression of selected NSCLC-relevant genes. In order to screen for possible 
molecular targets of PAX6 in NSCLC, we used real-time qPCR to measure changes of mRNA expression of the 
panel of 25 genes upon PAX6 knockdown. Selection of genes included in the panel was based on previous reports 
on predictive biomarkers published by our group37–43, as well as studies of downstream targets of PAX6 performed 
by other groups44–48. We chose the threshold fold change of 1,5 (or −1,5) as minimum sufficient to consider a 
gene to be affected by PAX6 knockdown. Noteworthy, in the NCI-H661 cell line, PAX6 knockdown caused mod-
erate but reproducible upregulation of CTGF, and downregulation of PTEN, VEGFD and SFRP2. While in the 
NCI-H460 upregulation of WNT2B was of note (Fig. 5).
Figure 3. Disease-specific survival according to PAX6 expression. Disease-specific Kaplan-Meier survival 
curves according to PAX6 expression in 103 resected NSCLC patients with regional nodal metastasis (pN+). 
The P-value is according to the log-rank test.
Figure 4. Phenotypic effects of PAX6 knockdown on NSCLC cell lines. (A) Migration of NCI-661 cells across 
porous membrane. (B) Proliferative activity of NCI-H460 and (C) NCI-661 cells. (D) soft agar colony formation 
assay in NCI-H460 cells. PAX6 knockdown efficiency is demonstrated in Fig. 5.
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Assessment of the correlation between PAX6 and target genes. To confirm the association 
between PAX6 expression and PAX6 target genes, we assessed correlations in a compendium of 18 000 gene 
expression data sets available from GEO using the ChIPXpress R package. Results show overall low scores, mean-
ing high correlations between expression levels of PAX6 and the target genes (Table 2).
Discussion
To our knowledge, we are the first group to report PAX6 protein expression in NSCLC. In the total NSCLC cohort 
we observed a trend towards longer survival in patients with high PAX6 expression. Among patients with nodal 
metastases, those with high PAX6 expression showed significantly increased survival.
Previous reports describing PAX6 expression in human malignancies dealt with tumours of brain and pan-
creas, which are the organs with tight developmental links to PAX6. Expression of PAX6 in lung cancer is a 
somewhat surprising finding, yet it is expected of malignant tumours to show gross aberrations in expression 
profiles compared to the corresponding normal tissues. We have previously experienced difficulties with finding a 
commercially available specific antibody against PAX6, which could be used for both Western blotting and stain-
ing of FFPE tissue sections. Several of the tested antibodies (marketed by manufacturers as specific for human 
PAX6) did produce bands of nearly correct size on Western blots, and did stain various cell types using IHC, but 
were shown to be non-specific in our validation tests. The antibody used in this study performed very well on 
Figure 5. Putative downstream target genes of PAX6 in NSCLC. PAX6 was transiently knocked down in two 
NSCLC cell lines. Expression of the target genes was measured by real-time qPCR. The amount of target gene 
was normalized to the average expression of the two human reference genes GUSB and TFRC, and is shown 




1 WNT2B 7482 1.2
2 SFRP2 6423 1.9
3 CTGF 1490 2.9
4 PTEN 5728 4.0
NA VEGFD (FIGF) 2277 NA
Table 2. Prediction and ranking of functional PAX6 target genes based on publicly available GEO datasets. 
Genes are ranked according to the ChIPXpress score, where a small score corresponds to a highly ranked gene.
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a Western blot with cells stably overexpressing PAX644 and siRNA-treated cells with endogenous expression of 
PAX6 (Fig. 1A). In FFPE pancreatic tissue sections it stained exclusively endocrine islets (Fig. 1B).
Statistical analyses of our TMA data revealed a non-significant trend for better DSS in patients with higher 
expression of PAX6. However, significantly improved survival was found among node-positive patients 
(P = 0.022). There is a lack of validated biomarkers for node-positive disease, which represents a substantial pro-
portion of patients with NSCLC. Involvement of regional lymph nodes is a major event which decreases chances 
for survival and dictates a need for adjuvant or neoadjuvant chemotherapy10. Therefore, emergence of PAX6 as a 
beneficial prognostic marker for node-positive patients is important. Further studies should dissect the molecular 
mechanisms explaining the tumour-suppressive action of PAX6, as well as evaluate whether its expression may 
predict response to anticancer therapy such as platinum-based therapy and novel targeted therapies.
In an attempt to explore the biological effect of PAX6 in NSCLC, we analysed changes in proliferation, migra-
tion and anchorage-independent growth after cells were transfected with siRNA against PAX6. Several inde-
pendent experiments did not provide significant evidence of shifts in proliferative activity of NSCLC cells upon 
transient knockdown of PAX6. However, a prominent effect was seen for migration capacity of NCI-H661 cells. 
Cells transfected with PAX6 siRNA were able to migrate actively through the porous membrane in CIM-plates 
along the serum gradient. Compared to these, control cells demonstrated very little if any migration. Similar 
results were obtained from the scratch assays analysed by the camera-based real-time cell monitoring instrument 
Incucyte (not shown). Inhibition of cancer cell migration by PAX6 fits well with the proposed tumour-suppressor 
role and with our survival data in pN+ patients. Although PAX6 is known to be a crucial regulator of cell migra-
tion during development of the eye and the brain34, as well as influencing cell migration when exogenously 
expressed in normal murine fibroblasts44, there are to our knowledge no publications on the effect of PAX6 on 
migration of cancer cells.
Overcoming anoikis and becoming capable of anchorage-independent growth is one of the core events in 
the malignant transformation of cells, as well as in establishing new tumour foci beyond the primary site49. In 
our study, PAX6-deficient NSCLC cells were able to grow much more actively in soft agar, than control cells. It is 
possible that in patients with node-positive disease, PAX6 decelerates further dissemination of the tumour and 
thus improves survival. Again, this is in line with our concept that PAX6 acts as a tumour suppressor in NSCLC. 
Others have shown that PAX6 increases glioma cell susceptibility to detachment an oxidative stress28. Zhao et 
al. indicated that A549 and H1299 NSCLC cell lines with stable knockdown of PAX6 had a lower rate of colony 
formation in soft agar compared to controls50. We had tested the mentioned cell lines (along with 5 other lines) 
for endogenous expression of PAX6 protein prior to starting the cell experiments for our study. We have observed 
that A549 and H1299 cells had very low levels of PAX6, when compared to the two cell lines which we chose to 
continue with (NCI-H460 and NCI-H661). Zhao et al.50 used a stable knockdown of PAX6 instead of a transient 
one, which potentially could lead to adaptations of cells to long-term deficit of PAX6 and alteration of related reg-
ulatory networks. This might explain the discrepancy between our results with respect to anchorage-independent 
growth. Luo et al. report that PAX6 activates A529 cell proliferation and invasion51, yet one may argue that over-
expressing PAX6 in a cell line with very low endogenous level of PAX6 might be less optimal approach than 
inducing knockdown of PAX6 in cells with high endogenous levels of PAX6.
The observed changes in expression of NSCLC-relevant genes may contribute to understanding of the molec-
ular mechanisms behind PAX6’s role in NSCLC. PAX6 upregulates a known tumor suppressor PTEN, as well 
as SFRP2 - an inhibitor of the WNT pathway. The genes inhibited by PAX6 (WNT2B and CTGF) have been 
previously shown to have pro-malignant roles in NSCLC52–54. SFRP2 and WNT2B belong to the WNT pathway, 
activation of which is important in lung cancer biology55. Our data suggest that PAX6 may inhibit WNT pathway 
through upregulation of its suppressor (SFRP2) and downregulation of its effector (WNT2B).
For in silico validation of PAX6 target genes, the ChIPXpress approach provides improved target gene pre-
diction compared to experimental information or database information alone56. We identified high correlations 
between PAX6 and the predicted target genes, which lends strength to our experimental findings. However, 
ChIPXpress relies on the assumption that transcription factor binding induces gene expression changes, which 
is not always the case. For example, genes may be regulated by numerous transcription factors collectively and 
variation in on transcription factor may not induce expression change. Further, ChIPXpress may not be able to 
properly rank genes that are lowly expressed, or genes that are regulated only in specific tissues or conditions. 
Lastly, ChIPXpress does not differentiate between positive or negative correlation, but rather indicates all regu-
lated genes.
The tumour suppressor role of PAX6 in NSCLC, which we propose in this paper, is in line with a number of 
methylation studies, which indicated that PAX6 promoter methylation is common in several cancers18 -21, includ-
ing NSCLC15–17, and is associated with disease recurrence18 and poor survival17,19.
Conclusion
We believe that our findings support the proposition of PAX6 as a valid and positive prognostic marker in NSCLC 
in node-positive patients. There is a need for further studies, which should provide further mechanistical explana-
tion for the role of PAX6 in NSCLC, in particular regarding target genes of PAX6 in this tumour group.
Materials and Methods
All methods were performed in accordance with the relevant guidelines and regulations.
Patients and tissues. Retrospectively, we identified 371 patients who were surgically resected with patho-
logical stage I to IIIA NSCLC at the University Hospital of North Norway and Nordland Central Hospital 
between 1990 and 2004. Primary tumour tissue was collected from the archives of the two respective pathological 
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departments. After exclusion of 36 patients due to inadequate paraffin-embedded formalin-fixed tissue blocks 
(n = 13), other malignancy within 5 years prior to diagnosis (n = 13) or radiotherapy or chemotherapy prior to 
surgery (n = 10), we were left with 335 eligible patients with complete demographic and clinicopathological data. 
The histopathological data were revised according to the 7th edition of UICC TNM classification of lung cancer 
and the newly revised classification for NSCLC adenocarcinoma57,58. A total of 103 patients had metastases to 
regional lymph nodes (pN+). Adjuvant chemotherapy was not yet introduced in Norway during this period 
(1990–2004). The last disease-specific survival (DSS) update was done in November 2011.
The Regional Committee for Medical and Health Research Ethics (2009/1393), the Data Protection Official 
for Research (NSD), and the Norwegian National Data Inspection Board approved this study. All patients were 
anonymized with each trial number. These numbers were initially linked to identity for only one purpose prior 
to collect clinical information. The Norwegian Social Science Data Service and the University Hospital’s Data 
Protection Office accepted this solution (2009/1393). Written consent from the patients was considered, but as 
this was a retrospective study where most of the material was more than 10 years old and most of the patients 
deceased, it was considered not needed. All data was analysed anonymously.
Microarray construction. Duplicate 0.6 mm core biopsies from the most representative areas of tumour 
cells (neoplastic epithelial cells) and tumour-surrounding stroma were collected from each surgical specimen 
using a tissue-arraying instrument (Beecher Instruments, Silver Springs, MD). Normal lung tissue localized dis-
tant from the primary tumour as well as lung tissue samples from 20 normal lungs from patients without any 
history of malignancy were also sampled. Eight tissue microarray blocks (TMAs) were constructed to include all 
the cores. The detailed methodology has been reported previously43,59.
Immunohistochemistry (IHC). Sections were deparaffinised with xylene and rehydrated with ethanol. 
Antigen retrieval was performed by placing the specimen in 0.01 mol/l citrate buffer at pH 6.0 and exposed to two 
repeated microwave heatings of 10 minutes at 450 W. The DAKO EnVision + System-HRP (DAB) kit was used as 
endogen peroxidase blocking. Primary antibody against PAX6 (AB2237, Millipore) was incubated overnight at 
4 °C. The DAKO EnVision + System-HRP (DAB) kit was used to visualize the antigen-antibody complexes. This 
yielded a brown reaction product at the site of the target antigen. As negative staining controls, the primary anti-
bodies were replaced with the primary antibody diluent. All TMA, including the negative controls, were stained 
in one single experiment. Finally, TMA slides were counterstained with haematoxylin to visualize the nuclei.
Scoring of immunohistochemistry. Viable parts of each anonymized core were scored independently 
and semiquantitatively by one pathologist and one oncologist, who was trained to score immunohistochemically 
stained sections (S.A.S and H.S) by light microscopy. When assessing a variable in a given core, the scorers were 
blinded to the outcome and score of the other observer. Only the neoplastic cell compartment (tumour epithe-
lial cells) was scored in this study as there was no expression detected in the tumour-surrounding stroma. The 
dominant staining intensity in tumour was scored as: 0 = negative, 1 = weak, 2 = intermediate or 3 = strong. We 
observed nuclear staining of varying intensity for PAX6, as well as some degree of cytoplasmic staining in cells 
with nuclear positivity. Nuclear and cytoplasmic staining as well as the density of tumour cells positive for PAX6 
were scored separately.
A mean score was calculated for the two tumour cell cores for each individual. In tumour, high expression 
was defined as intensity of nuclear expression ≥1. Similar scoring methods have been used in our previous 
IHC-scoring studies43,60,61 and by others62. Optimal statistical cut-off levels for high and low expression were used.
Cell cultures. Of seven NSCLC cell lines available at our lab only two had significant levels of endogenous 
PAX6 expression (NCI-H460 and NCI-H661), and those were chosen for experiments. Human large cell lung 
carcinoma cell lines NCI-H661 (ATCC HTB-183) and NCI-H460 (ATCC HTP-177) were grown in RPMI-1640 
(Sigma-Aldrich) with 10% FCS. Media for all cell lines contained 1% of mixed 100 U/ml penicillin and 100 mg/
ml streptomycin (cat#P0781, Sigma-Aldrich).
Western blotting. Cells were lysed directly in the NuPAGE® LDS Sample Buffer (NP0007, Life 
Technologies) with DTT. Samples were run on NuPAGE Novex 4–12% Bis-Tris gels (NP0322, Life Technologies), 
and blotted onto the Odyssey nitrocellulose membrane (LI-COR Biosciences, Lincoln, NE). Membranes were 
blocked for 1 hour in room temperature using Odyssey blocking buffer (LI-COR Biosciences). Primary and sec-
ondary antibodies were diluted in the blocking buffer, and membranes were incubated at room temperature for 
at least 1 hour. Washing was done after each antibody incubation 5 times for 5 minutes in TBS containing 0.1% 
Tween-20. Membranes were incubated with IRDye Coupled secondary antibodies, and images were acquired 
with the Odyssey Sa Infrared Imaging System (LI-COR Biosciences).
Antibodies used were rabbit polyclonal anti-Pax6 antibody 1:1200 (AB2237, Merck Millipore), rab-
bit anti-Actin 1:2000 (A2066, Sigma-Aldrich), anti-rabbit 800 CW 1:10 000 (#926-32214 and #926-32213, 
LI-COR Biosciences). Molecular weight markers used were SeeBlue Plus2 Prestained Standard (Invitrogen) and 
MagicMark XP Western Protein Standard (Invitrogen).
RNA interference. Cells were transfected in 6-well plates with human PAX6 siRNA (#114168 Silencer Select 
PAX6 siRNA, Ambion) using Lipofectamine 2000 (#11668–027, Invitrogen). A scrambled negative control (SCR) 
siRNA was included in all experiments (Silencer Negative Control #2 siRNA, Ambion). Cells were harvested 
48 hours after siRNA transfection. Transfection efficiency was routinely controlled using the BLOCK-iT fluores-
cent oligoes (#2013, Invitrogen) with typical proportion of transfected cells 85–100%. Knockdown of PAX6 was 
verified by Western blot and RT-qPCR.
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RNA extraction and RT-qPCR. Total RNA was extracted using the RNeasy Plus kit (#74134, Qiagen, 
Hilden, Germany). Reverse transcription of total RNA was performed with Superscript III Reverse Transcriptase 
kit (#18080–044, Invitrogen), using 150 ng random hexamer primers (Fermentas International Inc., Canada). 
dNTP mix was purchased from Promega (Madison, WI). We used 500 ng total RNA per 20 µl cDNA reaction. 
Primer pairs were designed using Primer 3 software (Whitehead Institute, Cambridge, MA) and synthesized by 
Invitrogen or Sigma, or purchased directly from Qiagen (supplementary Figure 2). For quantification of mRNA 
expression levels, a Stratagene MX3000P instrument (Stratagene, La Jolla, CA) was used. cDNA was amplified 
for 40 cycles in a 25 µl SYBR green PCR mix (Brilliant II SYBR Green QPCR master mix, Stratagene) contain-
ing 200 nM of each primer. Cycling conditions were as follows: 95 °C for 10 min followed by 40 cycles at 95 °C 
for 30 sec, 60 °C for 1 min and 72 °C for 30 sec. Duplicate PCR analyses were performed on each cDNA sample. 
The absence of genomic DNA and contaminations were confirmed by the inclusion of no reverse transcriptase 
(No RT) controls and no template controls (NTCs) respectively. The relative amount of target gene normal-
ized to the average expression of the two human reference genes GUSB and TFRC was determined using the 
ΔΔCT-method63.
Assessment of the correlation between PAX6 and target genes. Correlation of gene expression lev-
els between PAX6 and candidate target genes was assessed using ChIPXpress56. ChIPXpress is an R/Bioconductor 
package for prediction of functional transcription factor target genes through the combination of experimental 
results and large amounts of publicly available gene expression data from databases such as Gene Expression 
Omnibus (GEO, www.ncbi.nlm.nih.gov/geo/). The method is based on the observation that in spite of the inher-
ent heterogeneity of GEO datasets, the global correlation between a transcription factor and its possible target 
genes provides valuable information for functional ranking of the target genes. Briefly, a compendium of more 
than 18 000 gene expression samples from Affymetrix Human U133 Plus 2.0 microarrays have been normalized 
and standardized, and is provided as part of the ChIPXpress package. ChIPXpress combines the ranked list of tar-
get genes from the researcher’s own experiments with a ranking of target genes based on the GEO compendium. 
The output is a linear combination of the ranks, hence, a small score corresponds to a highly ranked gene. For 
more details, please refer to Wu et al.56.
Proliferation and migration assays. Assays were performed on the microelectric impedance-based 
xCELLigence platform (Roche) using E-plates (Roche, cat# 05469830001) for proliferation, and CIM-plates 
16 (Roche, cat# 05665817001) for migration as described previously44. Optimal cell numbers per well (5000 
NCI-H460 and 3000 NCI-H661 for proliferation and 20000 NCI-H661 for migration) were determined in initial 
titration experiments. At least 4 independent proliferation experiments, and 3 independent migration experi-
ments were performed.
Colony formation in soft agar. Colony formation in soft agar was performed by growing 1800 H460 cells 
in the upper layer of a two layer agar (500 μl 0.5% top agar and 500 μl 0.8% base agar) per well in a 12-well dish. 
Prior to growing in soft agar, cells were transfected with PAX6 siRNA and negative control (SCR) siRNA, respec-
tively, for 6 hours in a 6-well dish. After 3 weeks cells were fixated with 500 μl 10% methanol + 10% acetic acid per 
well for 20 minutes. Cell colonies were stained with 500 μl 0.01% crystal violet per well for 18 hours at 4 °C before 
counting.
Statistical methods. The statistical analyses were done using the SPSS 21 package (Chicago, IL). The χ2 test 
and Fishers exact tests were used to examine the associations between molecular marker expressions and the clin-
icopathological markers. r-values are the Spearman’s rank correlation coefficient. Plots of the DSS, according to 
marker expressions, were drawn using the Kaplan-Meier method, and the statistical significance between survival 
curves was assessed by the log rank test. The chosen endpoint, disease-specific survival (DSS), was calculated 
from the time of surgery to the time of lung cancer death.
In the multivariate analysis, statistically significant variables from the univariate analyses (P < 0.05) for pN+ 
patients were entered in a backward stepwise Cox regression analysis with a probability for stepwise entry and 
removal at 0.05 and 0.10, respectively. A P < 0.05 was considered statistically significant for all analyses.
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